

**Policy: MBP 314.0**

**Section: Medical Benefit Pharmaceutical Policy**

**Subject: Loqtorzi (toripalimab-tpzi)**

---

### **I. Policy:**

Loqtorzi (toripalimab-tpzi)

### **II. Purpose/Objective:**

To provide a policy of coverage regarding Loqtorzi (toripalimab-tpzi).

### **III. Responsibility:**

- A. Medical Directors
- B. Medical Management
- C. Pharmacy Department

### **IV. Required Definitions**

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. the department requiring/authoring the policy.
4. Devised – the date the policy was implemented.
5. Revised – the date of every revision to the policy, including typographical and grammatical changes.
6. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

### **V. Additional Definitions**

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards good medical treatment practiced by the general medical community;
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient

### **Medicaid Business Segment**

Medically Necessary — A service, item, procedure, or level of care compensable under the Medical Assistance program that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- i. Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- ii. Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- iii. Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

**DESCRIPTION:**

Toripalimab is a humanized IgG4 monoclonal antibody that inhibits programmed death receptor-1 (PD-1). PD-L1 and PD-L2 binding to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Toripalimab binds to the PD-1 receptor found on T cells, blocking interaction with the ligands PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of immune response, including antitumor response. Upregulation of PD-1 ligands occurs in some tumors, therefore signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.

**CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee**

**GRANDFATHER PROVISION** – Members already established on therapy are eligible for approval as long as there is medical record documentation that the safety and effectiveness of use for the prescribed indication is supported by Food and Drug Administration (FDA) approval or adequate medical and scientific evidence in the medical literature.

Loqtorzi (toripalimab-tpzi) will be considered medically necessary for all lines of business when ALL of the following criteria are met:

- Medical record documentation that Loqtorzi is prescribed by an oncologist **AND**
- Medical record documentation of age greater than or equal to 18 years **AND**
- One of the following:
  - Medical record documentation that Loqtorzi is being given as first-line treatment in combination with cisplatin and gemcitabine **AND**
  - Medical record documentation of a diagnosis of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)

**OR**

- Medical record documentation that Loqtorzi is being used as a single agent **AND**
- Medical record documentation of a diagnosis of recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC) **AND**
- Medical record documentation of disease progression on or after a platinum-containing chemotherapy.

**AUTHORIZATION DURATION:** Initial approval will be for **12 months**. Subsequent approvals will be for an additional **12 months** and will require medical record documentation of continued disease improvement or lack of disease progression. The medication will no longer be covered if patient experiences toxicity or worsening of disease.

Note: For Medicaid (GHP Family), any requests for services that do not meet criteria set in the PARP will be evaluated on a case-by-case basis.

**LINE OF BUSINESS:**

**Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.**

**REFERENCES:**

1. Loqtorzi [Prescribing Information]. Redwood City CA. Coherus BioSciences, Inc. October 2023.

This policy will be revised as necessary and reviewed no less than annually.

**Devised:** 2/23/24

**Revised:**

**Reviewed:**

**MA UM Committee approval:** 5/22/24